COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

-70.18

Decreased from previous period

Negative OCF/share while 3088.T has 0.57. Joel Greenblatt would question the viability of operations in comparison.

Free Cash Flow per Share

-91.39

Decreased from previous period

Both firms show negative FCF/share. Martin Whitman might see an industry-wide capital intensity challenge.

Capex-to-Operating Cash Flow

-30.23%

Decreased from previous period

Negative ratio while 3088.T is 270.71%. Joel Greenblatt would question whether the firm’s OCF is negative or capex is abnormally large.

Income Quality Ratio (OCF / Net Income)

-2.46

Decreased from previous period

Negative ratio while 3088.T is 0.06. Joel Greenblatt would check if we have far worse cash coverage of earnings.

Operating Cash Flow-to-Sales Ratio

-5.59%

Decreased from previous period

Negative ratio while 3088.T is 0.24%. Joel Greenblatt would see if the company’s revenues or cash flows are fundamentally flawed.

Select Chart Metric:

3349.T Cash Flow Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

-70.18

Decreased from previous period

Negative OCF/share while 3088.T has 0.57. Joel Greenblatt would question the viability of operations in comparison.

Free Cash Flow per Share

-91.39

Decreased from previous period

Both firms show negative FCF/share. Martin Whitman might see an industry-wide capital intensity challenge.

Capex-to-Operating Cash Flow

-30.23%

Decreased from previous period

Negative ratio while 3088.T is 270.71%. Joel Greenblatt would question whether the firm’s OCF is negative or capex is abnormally large.

Income Quality Ratio (OCF / Net Income)

-2.46

Decreased from previous period

Negative ratio while 3088.T is 0.06. Joel Greenblatt would check if we have far worse cash coverage of earnings.

Operating Cash Flow-to-Sales Ratio

-5.59%

Decreased from previous period

Negative ratio while 3088.T is 0.24%. Joel Greenblatt would see if the company’s revenues or cash flows are fundamentally flawed.

Select Chart Metric: